Welcome to our dedicated page for Calidi Biotherapeutics news (Ticker: $CLDI), a resource for investors and traders seeking the latest updates and insights on Calidi Biotherapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Calidi Biotherapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Calidi Biotherapeutics's position in the market.
Calidi Biotherapeutics Inc. (NYSE American: CLDI) announced the acceptance of three abstracts for presentation at the 2024 ASCO Annual Meeting. The abstracts focus on their innovative programs for the treatment of high-grade glioma and solid tumors. Calidi will present updates on their CLD-101, RTNova, and CLD-201 programs, showcasing their cutting-edge therapeutic candidates.